1. Microinduction of buprenorphine/naloxone: a review of the literature;Ahmed;Am. J. Addict.,2021
2. American Society of Addiction Medicine. 2020 National Practice Guideline - OUD. Rockville, MD; 2020. https://www.asam.org/Quality-Science/quality/2020-national-practice-guideline. Accessed November 9, 2021.
3. American Society of Addiction Medicine. (2021). ASAM Applauds Re-Introduction of Mainstreaming Addiction Treatment (MAT) Act. Retrieved from https://www.asam.org/docs/default-source/advocacy/letters-and-comments/21-02-24-x-waiver-press-release_final1f9b3a9472bc604ca5b7ff000030b21a.pdf?Status=Temp&sfvrsn=92275ac2_2
4. Hospital buprenorphine program for opioid use disorder is associated with increased inpatient and outpatient addiction treatment;Christian;J. Hosp. Med.,2021
5. Improve access to care for opioid use disorder: a call to eliminate the X-waiver requirement now;D'Onofrio;Ann. Emerg. Med.,2021